Lim, Lee-Ling and Lau, Eric S. H. and Cheung, Johnny T. K. and Chan, Siew Pheng and Ji, Linong and Lim, Soo and Sirinvaravong, Sirinart and Unnikrishnan, A. G. and Luk, Andrea O. Y. and Cortese, Viviana and Durocher, Alexandra and Chan, Juliana C. N. (2023) Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register. Diabetes Obesity & Metabolism, 25 (1). pp. 208-221. ISSN 1462-8902, DOI https://doi.org/10.1111/dom.14865.
Full text not available from this repository.Abstract
Aims: To explore the patterns of use of oral glucose-lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D), focusing on sulphonylureas (SUs), and to describe patient profiles according to treatment regimen. Methods: We conducted a cross-sectional analysis of data from adults with T2D from 11 Asian countries/regions with structured assessment enrolled in the prospective Joint Asia Diabetes Evaluation (JADE) register between November 2007 and December 2019. Patients receiving insulin and/or injectable glucagon-like peptide-1 receptor agonists were excluded. Results: Amongst 62 512 patients (mean +/- standard deviation age: 57.3 +/- 11.8 years; 53.6% men), 54 783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU-based therapy with variations amongst countries/regions. Overall, 79.5% of SU regimens were based on SUs plus metformin, and 22.1% on SUs plus dipeptidyl peptidase-4 inhibitors. Among SU users, gliclazide was most commonly prescribed (46.7%), followed by glimepiride (40.0%) and glibenclamide (8.1%). More gliclazide users entered the cohort with glycated haemoglobin levels <53 mmol/mol (7%) than non-gliclazide SU users (odds ratio OR] 1.09, 95% CI 1.02-1.17), with less frequent self-reported hypoglycaemia in the 3 months before registration (OR 0.81, 95% CI 0.72-0.92; adjusted for sociodemographic factors, cardiometabolic risk factors, complications, use of other OGLDs, country/region and year of registration). Conclusion: In Asia, SUs are a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.
| Item Type: | Article |
|---|---|
| Funders: | Ashfield MedComms GmbH, Hong Kong Government Innovation and Technology Commission for providing precision diabetes care and Chief Executive Officer of Asia Diabetes Foundation, Viatris Pharmaceutical, Servier |
| Uncontrolled Keywords: | Sulphonylureas; Asian patients; Type 2 diabetes (T2D) |
| Subjects: | Q Science > QD Chemistry R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine > Medicine Department |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 29 Nov 2023 03:40 |
| Last Modified: | 29 Nov 2023 03:40 |
| URI: | http://eprints.um.edu.my/id/eprint/39428 |
Actions (login required)
 |
View Item |
